This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

Castle Biosciences, Inc.
11/5/2026
Good afternoon and welcome to CASEL Bioscience third quarter 2026 conference call. As a reminder, today's call is being recorded. We will begin today's call with opening remarks and introductions, followed by a question and answer session. I would now like to turn the call over to Camilla Zuckero, Vice President, Investor Relations and Corporate Affairs. Thank you. You may begin.
Thank you, Operator. Good afternoon, everyone. Welcome to CASEL Biosciences' third quarter 2026 results conference call. Joining me today are CASEL's founder, president, and chief executive officer, Derek Maetzold, and chief financial officer, Frank Stokes. Information recorded on this call speaks only as of today, November 5, 2026. Therefore, if you are listening to the replay or reading the transcript of this call, any time-sensitive information may no longer be accurate. A recording of today's call will be available on the Investor Relations page of the company's website for approximately three weeks following the conclusion of the call. Before we begin, I would like to remind you that some of the statements made today will contain forward-looking statements, including statements about expected addressable markets, statements containing projections regarding future events or our future financial or operational results and performance. including our anticipated 2026 total revenue, test report volume growth guidance and positive adjusted EBITDA for the fourth quarter, full year 2026 and full year 2027 and the impact of our investments and growth initiatives including our ability to achieve long-term growth and drive stockholder value. Forward-looking statements are based upon current expectations and involve inherent risks and uncertainties and there can be no assurances that the results contemplated in these statements will be realized. A number of factors and risks could cause actual results to differ materially from those contained in these forward looking statements. Please refer to the risk factors in our most recent SEC filings for more information. These forward looking statements speak only as of today and we assume no obligation to update or revise these forward looking statements as circumstances change. In addition, some of the information discussed today includes non-GAAP financial measures such as adjusted revenue, adjusted gross margin, and adjusted EBITDA that have not been calculated in accordance with U.S. GAAP. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures are presented in the tables at the end of our earnings release issued earlier today, which has been posted on the investor relations page of the company's website. I will now turn the call over to Derek.
Thank you, Camilla, and good afternoon, everyone. Our team closed out a very successful third quarter, reflecting our focused execution and disciplined expense management, underscored by the clinical value our tests provide to clinicians and their patients. We delivered revenue of $102.9 million, 24% growth compared to the third quarter of 2025, primarily driven by tissue cipher test report volume, which grew by 47% compared to the third quarter of 2025. We generated $19.7 million in net cash provided by operating activities and end of the quarter with cash, cash equivalents, and marketable investment securities totaling approximately $278 million. We are increasing our full year 2026 total revenue guidance from our prior range of $365 million to $375 million to $385 million to $395 million. This represents a $20 million increase at the midpoint, reflecting our year-to-date performance and anticipated continued strength in tissue cipher test volume growth. Importantly, at the midpoint, our updated guidance represents a $45 million increase from where we entered the year. Now, I will walk you through the business highlights from the third quarter, and then Frank will provide additional financial highlights before we turn to your questions. But first, let me take a moment to thank the CASEL team. Without each person's dedication to serving our patients, we would not be in the strong financial position we are in today. So thank you, Team CASEL. Now, let's start with our core revenue drivers for 2026, DecisionDx Melanoma and TissueCypher. For DecisionDx Melanoma, we delivered 10,177 test reports in the third quarter of 2026. making our fifth consecutive quarter exceeding 10,000 test reports and contributing to 5% year-over-year volume growth through the first nine months of 2026 compared to the first nine months of 2025. Decision X melanoma remains a central priority for a dermatology commercial organization. We've aligned commercial focus and incentive structures to reinforce that priority while leveraging our established customer relationships to increase use of our broader portfolio of dermatology tests. Our objective is to drive continued adoption of DecisionDx melanoma while building future growth opportunities across our dermatology tests. With DecisionDx melanoma continuing to provide a durable foundation for our dermatology business and reflecting third quarter and year-to-date test report volume, we are refining our outlook for full year 2026 DecisionDx melanoma test volume growth and now expect mid-single-digit year-over-year growth compared with 2025. Now, turning to tissue cipher. During the third quarter, we delivered 15,574 test reports, representing strong growth of 47% compared to the third quarter of 2025. This performance reflects continued momentum in our commercial execution, driven by increased utilization among our existing clinician base, and to a lesser degree, the addition of new ordering clinicians. Based on our year-to-date performance, we are reiterating our expectations for full-year 2026 TissueCypher test report garden growth of 50% to 52% compared to 2025. Alongside this strong commercial performance, we remain focused on expanding the body of clinical evidence, supporting TissueCypher's utility, and helping physicians make more informed, risk-aligned management decisions for patients with Barrett's esophagus disease. In September, we announced the publication of a new decision modeling study in the Annals of Gastroenterology. This study, which leveraged data from 699 patients across five previously published clinical validation studies, demonstrated that incorporating tissue cycle results into clinical decision-making could significantly improve the portion of patients receiving appropriate management, including in patients with nondysplastic and short-segment Barrett's, who are considered clinically to be at lower risk for neoplastic progression. In patients with nondysplastic Barrett's disease, whose disease did progress, use of tissue cipher to guide management decisions increased appropriate management in the form of endoscopic eradication therapy or short interval surveillance from 30.4% to 56.9%. Notably, among patients with non-dysplastic Barrett's who later progressed to high-grade dysplasia or esophageal cancer, tissue cypher guided management would have nearly doubled the proportion of patients receiving appropriate escalation of care from approximately 30% to 57%, while also reducing unnecessary procedures among those patients who did not progress. We believe these findings add to the growing body of evidence supporting TissueSucker's clinical value and further reinforce its role in helping physicians tailor patient management based on individualized risk of disease progression. Now, let's move back to dermatology and focus on our advanced ADTX test. During the third quarter of 2026, we delivered 1,109 test reports, reinforcing the value of our advanced ADTX test. We are particularly pleased with the recent publication of a new study in dermatology and therapy highlighting, one, the challenges patients with moderate to severe atopic dermatitis experience in achieving their treatment goals, and two, strong patient interest in molecular testing to help guide systemic therapy selection. Among patients who had been treated with targeted systemic therapies, 55% modified their treatment due to lack of efficacy. Overall, 83% of respondents expressed interest in molecular testing to guide treatment selection, increasing to 94% among those open to initiating a new systemic therapy. Further, in a real-world clinical use study that was presented in June at the Revolutionizing Atopic Dermatitis, or RAD, conference, found 98% of patients tested had their systemic treatment aligned with our advanced ADTX test results. meaning the 94% interest in patients new to systemic therapy who are interested in molecular testing aligns well with the 98% that Dr. Ames and colleagues reported at the RAD conference. We believe these findings support the clinical impact that our test is having on patient care. And with that, I will now turn the call over to Frank. Thank you, Derek. Good afternoon.
You're reading a preview of the CSTL Q3 2026 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing